The stock has a consensus rating of "Hold" and an average target price of $42.23. They now have a $35.00 target price on the stock. The company also recently lost a big patent case for its top-selling drug Copaxone, which moved investors to call for a management changes.
Cantor analyst Louise Chen says neither, while reiterating a Hold rating on the stock and lowering his price target to $27 (from $31), which represents a potential upside of 25% from where the stock is now trading.
Teva Pharmaceutical Industries Limited (TEVA) has the market capitalization of $24.4 Billion. Oppenheimer Holdings, Inc. set a $43.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a "buy" rating in a research note on Thursday, April 6th. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". The firm now has a "hold" rating on the stock.
Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 32.34 on Monday. It has a 36-month beta of 0.46, so you might not be in for a bumpy ride. Teva Pharmaceutical Industries Limited (TEVA) is a part of Healthcare sector and belongs to Drug Manufacturers - Other industry.
It is now trading at $23.75 marginally under the 50 day moving average which is $32.05 and which is just a bit below the 200 day moving average of $32.28.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 12.5933% during midday trading on Friday, hitting $20.7591. The company reported $1.02 earnings per share for the quarter, missing analysts' consensus estimates of $1.06 by $0.04. Return on Equity (ROE) stands at 0.3% and Return on Investment (ROI) of 1.1 percent.
They expect $1.06 EPS, down 17.92% or $0.19 from last year's $1.25 per share. During the same quarter in the previous year, the company earned $1.25 earnings per share.
Brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce $5.85 billion in sales for the current quarter, according to Zacks. Currently Analysts have a mean recommendation of 2.50 on the shares. If you are accessing this news story on another site, it was illegally copied and reposted in violation of global trademark & copyright legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/08/04/royal-bank-of-canada-downgrades-teva-pharmaceutical-industries-limited-nyseteva-to-underperform.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. The overall volume in the last trading session was 31.89 Million shares. Teva Pharmaceutical Inds Ltd now has $24.27 billion valuation. Whereas, in last 21 trading days (one month) was surged -27.39% and slashed in last 63 trading days (quarter) of -23.06%. Finally, NEXT Financial Group Inc raised its position in Teva Pharmaceutical Industries Limited by 150.3% in the second quarter.
Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock.
Tortoise Investment Management Llc holds 0.78% of its portfolio in Nuveen Select Tax Free Incom Portfolio 2 for 169,146 shares. ST Germain D J Co. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock. Investors measure stock performance on the basis of a company's earnings power. This has boosted sales for some companies, but Teva has been hurt by the fact that it's making less money per product.
The world's largest producer of generic medicines, which is based in Israel, has been without a permanent CEO since Eroz Vigodman resigned in February amid reports of a bribery investigation by the Israeli Police.